Oncotarget

Research Papers:

Cytotoxic lanostane-type triterpenoids from the fruiting bodies of Ganoderma lucidum and their structure–activity relationships

Shaodan Chen, Xiangmin Li, Tianqiao Yong, Zhanggen Wang, Jiyan Su, Chunwei Jiao, Yizhen Xie and Burton B. Yang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:10071-10084. https://doi.org/10.18632/oncotarget.14336

Metrics: PDF 2274 views  |   HTML 2478 views  |   ?  


Abstract

Shaodan Chen1,2,*, Xiangmin Li1,2,*, Tianqiao Yong1,2,*, Zhanggen Wang3, Jiyan Su1,2, Chunwei Jiao2, Yizhen Xie1,2, Burton B. Yang4,5

1State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou, China

2Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China

3College of Chinese Materia Medica, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China

4Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada

5Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

*These authors have contributed equally to this work

Correspondence to:

Yizhen Xie, email: 13622216490@126.com

Burton B. Yang, email: byang@sri.utoronto.ca

Keywords: Ganoderma lucidum, lanostane-type triterpenoids, cytotoxicity, 3D-QSAR

Received: July 25, 2016     Accepted: December 01, 2016     Published: December 28, 2016

ABSTRACT

We conducted a study of Ganoderma lucidum metabolites and isolated 35 lanostane-type triterpenoids, including 5 new ganoderols (1-5). By spectroscopy, we compared the structures of these compounds with known related compounds in this group. All of the isolated compounds were assayed for their effect against the human breast carcinoma cell line MDA-MB-231 and hepatocellular carcinoma cell line HepG2. Corresponding three-dimensional quantitative structure–activity relationship (3D-QSAR) models were built and analyzed using Discovery Studio. These results provide further evidence for anti-cancer constituents within Ganoderma lucidum, and may provide a theoretical foundation for designing novel therapeutic compounds.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14336